Investment in biopharmaceutical companies has increased in 2024 relative to 2022 and 2023, when initial public offerings fell from record levels followed by a drop in venture capital funding, but the rising biotechnology tide has not lifted all ships in the sector.
Financial Market Conditions Still Choppy As Rising Tide Has Yet To Lift All Ships
Some Boats Still Need To Sink Ahead Of Greater Gains
Venture capital funding is up, and initial and follow-on public offerings are growing, but the building wave of investment in biopharma has not reached all companies.
